| Q27341873 | 2014 AHA/ACC/HRS guideline for the management of patients with atrial fibrillation: a report of the American College of Cardiology/American Heart Association Task Force on practice guidelines and the Heart Rhythm Society |
| Q38073833 | A pragmatic strategy for the review of clinical evidence |
| Q37417509 | A systematic review of Cochrane anticoagulation reviews. |
| Q37741927 | Age-specific incidence, outcome, cost, and projected future burden of atrial fibrillation-related embolic vascular events: a population-based study |
| Q24241777 | Anticoagulants for preventing recurrence following presumed non-cardioembolic ischaemic stroke or transient ischaemic attack |
| Q24234617 | Antiplatelet agents and anticoagulants for hypertension |
| Q58040934 | Antiplatelet therapy for preventing stroke in people with atrial fibrillation |
| Q52657350 | Atrial Cardiopathy and the Risk of Ischemic Stroke in the CHS (Cardiovascular Health Study). |
| Q28084658 | Atrial cardiopathy: a broadened concept of left atrial thromboembolism beyond atrial fibrillation |
| Q38981275 | Atrial fibrillation and chronic kidney disease: struggling through thick and thin. |
| Q30238631 | Cardioembolic Stroke |
| Q36336822 | Comparison of hemostatic dressings for superficial wounds using a new spectrophotometric coagulation assay. |
| Q37342387 | Current management of atrial fibrillation: an observational study in NHS primary care |
| Q37247723 | Deficits in discharge documentation in patients transferred to rehabilitation facilities on anticoagulation: results of a systemwide evaluation. |
| Q24200617 | Direct thrombin inhibitors and factor Xa inhibitors for atrial fibrillation |
| Q94337721 | Direct thrombin inhibitors and factor Xa inhibitors for atrial fibrillation |
| Q37442492 | Does CHA2DS2-VASc improve stroke risk stratification in postmenopausal women with atrial fibrillation? |
| Q38261199 | Dual antiplatelet therapy in the anticoagulated patient undergoing percutaneous coronary intervention risks, benefits, and unanswered questions |
| Q45813085 | Effect of cardiovascular drug classes on all-cause mortality among atrial fibrillation patients treated in primary care in Sweden: a cohort study |
| Q42676674 | Effectiveness and patient safety of platelet aggregation inhibitors in the prevention of cardiovascular disease and ischemic stroke in older adults - a systematic review |
| Q42676634 | Effectiveness and safety of vitamin K antagonists and new anticoagulants in the prevention of thromboembolism in atrial fibrillation in older adults - a systematic review of reviews and the development of recommendations to reduce inappropriate pres |
| Q37479988 | Effects of prescribed antithrombotics and other cardiovascular pharmacotherapies on all-cause mortality in patients with diabetes and atrial fibrillation - a cohort study from Sweden using propensity score analyses |
| Q28081598 | Efficacy and safety of oral anticoagulants versus aspirin for patients with atrial fibrillation: a meta-analysis |
| Q36069462 | Efficacy and safety of warfarin in dialysis patients with atrial fibrillation: a systematic review and meta-analysis. |
| Q44486681 | Ethnicity and stroke risk in patients with atrial fibrillation |
| Q91649347 | Evidence-Practice Gaps in Postdischarge Initiation With Oral Anticoagulants in Patients With Atrial Fibrillation |
| Q38169038 | Factors influencing the decline in stroke mortality: a statement from the American Heart Association/American Stroke Association |
| Q35900767 | Genetic and environmental factors determining clinical outcomes and cost of warfarin therapy: a prospective study |
| Q92994476 | Guideline-concordant initiation of oral anticoagulant therapy for stroke prevention in older veterans with atrial fibrillation eligible for Medicare Part D |
| Q37701367 | Imaging of contrast medium extravasation in anticoagulation-associated intracerebral hemorrhage with dual-energy computed tomography |
| Q33949432 | Impact of prescribed medications on patient safety in older people |
| Q37725772 | Improving anticoagulation in atrial fibrillation: observational study in three primary care trusts |
| Q47291952 | Incidence of thromboembolic and bleeding events in patients with newly diagnosed nonvalvular atrial fibrillation: An Asian multicenter retrospective cohort study in Singapore |
| Q90194114 | Is Anticoagulation Necessary for Severely Disabled Cardioembolic Stroke Survivors? |
| Q34242062 | Is isolated aphasia associated with atrial fibrillation? A prospective study |
| Q49643122 | Is the Risk of Bleeding Among Older Adults With Atrial Fibrillation Lower With Antiplatelet Compared With Oral Anticoagulants? |
| Q95724841 | Left Atrial Appendage Closure Device With Delivery System: A Health Technology Assessment |
| Q41065525 | Left Atrial and Left Atrial Appendage 4D Blood Flow Dynamics in Atrial Fibrillation |
| Q33713422 | Management of Atrial Fibrillation: Translating Clinical Trial Data into Clinical Practice |
| Q39556840 | Modelling the cost-effectiveness of pharmacist-managed anticoagulation service for older adults with atrial fibrillation in Singapore. |
| Q24201386 | Multiple versus one or more antiplatelet agents for preventing early recurrence after ischaemic stroke or transient ischaemic attack |
| Q42907047 | New Approaches to Stroke Prevention in Atrial Fibrillation |
| Q35566692 | Optimal antithrombotic strategy in patients with atrial fibrillation after coronary stent implantation |
| Q38176288 | Optimizing antithrombotic therapy after coronary stent implantation in patients on chronic oral anticoagulation |
| Q89891735 | Outcomes Associated With Oral Anticoagulants Plus Antiplatelets in Patients With Newly Diagnosed Atrial Fibrillation |
| Q34712397 | Patterns of warfarin use in subgroups of patients with atrial fibrillation: a cross-sectional analysis of 430 general practices in the United Kingdom. |
| Q33585665 | Percutaneous Left Atrial Appendage Exclusion Therapy: Who, Why and How? |
| Q37425335 | Pharmacogenetics and stroke |
| Q37108889 | Potential impact of new oral anticoagulants on the management of atrial fibrillation-related stroke in primary care |
| Q37382897 | Practical Issues to Prevent Stroke Associated with Non-valvular Atrial Fibrillation |
| Q89092899 | Predictors of oral anticoagulant non-prescription in patients with atrial fibrillation and elevated stroke risk |
| Q38651209 | Probing oral anticoagulation in patients with atrial high rate episodes: Rationale and design of the Non-vitamin K antagonist Oral anticoagulants in patients with Atrial High rate episodes (NOAH-AFNET 6) trial |
| Q41159155 | Prolonged Cardiac Monitoring to Detect Atrial Fibrillation after Cryptogenic Stroke or Transient Ischemic Attack: A Meta-Analysis of Randomized Controlled Trials. |
| Q37599572 | Recent time trends in incidence, outcome and premorbid treatment of atrial fibrillation-related stroke and other embolic vascular events: a population-based study |
| Q37613761 | Reducing the risk of stroke in elderly patients with non-valvular atrial fibrillation: a practical guide for clinicians |
| Q35877931 | Risk of Ischemic Stroke after Intracranial Hemorrhage in Patients with Atrial Fibrillation |
| Q40333529 | Risk of major bleeding and stroke associated with the use of vitamin K antagonists, nonvitamin K antagonist oral anticoagulants and aspirin in patients with atrial fibrillation: a cohort study |
| Q55090406 | Risk of stroke and transient ischaemic attack in patients with a diagnosis of resolved atrial fibrillation: retrospective cohort studies. |
| Q38086826 | Screening, isolation, and decolonization strategies for vancomycin-resistant enterococci or extended spectrum Beta-lactamase-producing organisms: a systematic review of the clinical evidence and health services impact. |
| Q28359631 | Stroke Prevention in Atrial Fibrillation: Focus on Latin America |
| Q36418118 | Stroke prevention: managing modifiable risk factors |
| Q41486453 | The association between kidney function and major bleeding in older adults with atrial fibrillation starting warfarin treatment: population based observational study |
| Q36409803 | The role of contraindications in prescribing anticoagulants to patients with atrial fibrillation: a cross-sectional analysis of primary care data in the UK. |
| Q47559889 | Treatment of Atrial Fibrillation in Patients with Dementia: A Cohort Study from the Swedish Dementia Registry |
| Q36449900 | Trends in the management of atrial fibrillation: A neurologist's perspective |
| Q28553496 | Under-prescribing of Prevention Drugs and Primary Prevention of Stroke and Transient Ischaemic Attack in UK General Practice: A Retrospective Analysis |
| Q55359342 | Updates on Prevention of Cardioembolic Strokes. |
| Q89408614 | Variation in anticoagulation for atrial fibrillation between English clinical commissioning groups: an observational study |
| Q53759438 | Venous Thromboembolism in Primary Nephrotic Syndrome - Is the Risk High Enough to Justify Prophylactic Anticoagulation? |
| Q37478238 | Warfarin in vulnerable older adults with atrial fibrillation |
| Q46989595 | Warfarin prevails for stroke prevention in atrial fibrillation--even in octogenarians |
| Q40646597 | Warfarin treatment and risk of myocardial infarction - A cohort study of patients with atrial fibrillation treated in primary health care |
| Q57302446 | Warfarin: The End or the End of One Size Fits All Therapy? |
| Q49347395 | Warfarin: better the devil you know |